RxDoctor Payments Data

Kelly Farrow, NP

Family · Rochester, NYNPI 1730560103

Payments from drug & device makers

$12,774in general payments, 2019–2025

Across 69 payments — averaging $185.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$9K
  • Gilead$2K
  • Janssen Scientific Affairs, LLC$1K
  • Theratechnologies Inc.$232
  • Janssen Products, LP$85
  • Medline Industries LP$41
  • plus $88 from 3 others

What the payments were for

  • Consulting fees$8,41066%
  • Travel & lodging$1,23810%
  • Food & beverage$3,04224%
  • Education$851%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,774 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$8,497
Medicare patients
25
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala197$826,592
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf44$196,893
DovatoDolutegravir Sodium/Lamivudine55$152,141
TivicayDolutegravir Sodium72$150,956
JulucaDolutegravir/Rilpivirine36$117,437
TriumeqAbacavir/Dolutegravir/Lamivudi32$113,490
CabenuvaCabotegravir/Rilpivirine13$78,318
DescovyEmtricitabine/Tenofov Alafenam27$58,463
PrezcobixDarunavir/Cobicistat17$39,554
IsentressRaltegravir Potassium20$37,775
PrezistaDarunavir12$24,229
Darunavir20$22,426
PifeltroDoravirine14$21,800
Breo ElliptaFluticasone/Vilanterol23$8,626
Combivent RespimatIpratropium/Albuterol Sulfate11$5,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,759$885,056224 claims
Viiv Healthcare CompanyDovato, Tivicay, Juluca, Triumeq, Cabenuva$9,410$612,342208 claims
Janssen Products, LPSymtuza$85$196,89344 claims
Johnson & JohnsonPrezcobix$31$39,55417 claims
Janssen Scientific Affairs, LLCPrezista$1,160$24,22912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →